Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Cost of Revenue: 2022-2024

Historic Cost of Revenue for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $33.3 million.

  • Axsome Therapeutics' Cost of Revenue rose 41.19% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.7 million, marking a year-over-year increase of 51.37%. This contributed to the annual value of $33.3 million for FY2024, which is 27.77% up from last year.
  • As of FY2024, Axsome Therapeutics' Cost of Revenue stood at $33.3 million, which was up 27.77% from $26.1 million recorded in FY2023.
  • Axsome Therapeutics' Cost of Revenue's 5-year high stood at $33.3 million during FY2024, with a 5-year trough of $5.2 million in FY2022.
  • Moreover, its 3-year median value for Cost of Revenue was $26.1 million (2023), whereas its average is $21.5 million.
  • Data for Axsome Therapeutics' Cost of Revenue shows a peak YoY spiked of 401.44% (in 2023) over the last 5 years.
  • Axsome Therapeutics' Cost of Revenue (Yearly) stood at $5.2 million in 2022, then surged by 401.44% to $26.1 million in 2023, then climbed by 27.77% to $33.3 million in 2024.